Delorean Corporation Ltd (ASX:DEL) Welcomes Regulatory Reforms for Renewable Gas
Delorean Corporation Ltd (ASX:DEL) announces regulatory reforms that enhance its renewable gas projects and biomethane market viability in Australia.
Tag: Regulatory News & Compliance
Dexus (ASX:DXS) Announces Portfolio Valuation Increase and Estimated Distribution
Dexus (ASX:DXS) reports a $55M portfolio valuation increase and announces an 18.0 cents per security distribution for H1 FY25.
PYC Therapeutics (ASX:PYC) Aligns with FDA on Registrational Trial Design for RP11 Treatment
PYC Therapeutics (ASX:PYC) aligns with the FDA on registrational trial design for its RP11 treatment, advancing VP-001 to Phase 2/3 studies.
Avenira Limited (ASX:AEV) Announces Mine Management Plan Approval
Avenira Limited (ASX:AEV) secures Northern Territory Government approval for Wonarah Phosphate Project, moving towards DSO operations launch in Q4.
Diatreme Resources (ASX:DRX) Awarded Major Project Status for Northern Silica Project
Diatreme Resources (ASX:DRX) secures Major Project Status for Northern Silica Project, enhancing support and regional growth.
Dubber Corporation Limited (ASX:DUB) Announces Recovery Actions After $26.6m Misappropriation
Dubber Corporation Limited (ASX:DUB) initiates recovery actions after discovering $26.6m in misappropriated company funds.
Lunnon Metals (ASX:LM8) Completes Robust Scoping Study for Lady Herial Deposit
Lunnon Metals (ASX:LM8) completes a robust scoping study for its Lady Herial gold deposit, highlighting strong financial outcomes and strategic negotiations.
Challenger Limited (ASX:CGF) Supports APRA’s New Annuity Capital Settings
Challenger Limited (ASX:CGF) supports APRA’s new capital settings for annuities, enhancing Australia’s retirement income market.
PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.
Radiopharm Theranostics (ASX:RAD) Receives FDA Fast Track for RAD101
Radiopharm Theranostics (ASX:RAD) secures FDA Fast Track for RAD101, advancing its Phase 2 trial in brain metastases imaging.